Special Drug Use Surveillance Study of Ceprotin for Intravenous Injection 1000IU (All-Case Surveillance) in Congenital Protein C Deficiency

What this Trial Is About

Researchers are conducting a study in Japan to observe the use of Freeze-dried Human Protein C Concentrate (TAK-662) in people with congenital protein C deficiency. The main goal is to monitor the occurrence of side effects and assess how this treatment performs in managing the condition. The study is observational and focuses on real-world use without altering routine medical practices. Participants will receive TAK-662 through intravenous injection as part of their standard care. The study records the administration of TAK-662 and observes participants for adverse events over 12 months. For those needing long-term supplementation after initial or short-term treatment, monitoring may extend up to 24 months. The study sponsor does not influence treatment decisions but collects data on treatment effects and safety. During the study, participants will be regularly evaluated for any treatment-emergent adverse events, including specific complications such as venous thromboembolism and purpura fulminans. The research team collects information throughout the follow-up period to understand the safety profile of TAK-662. Participants' health and any side effects are closely monitored to provide comprehensive safety data over the study duration.

A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants With Congenital Protein C Deficiency